Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Medtech, a surgical robotics firm concerned with central nervous system procedures, has commenced a listing as part of compartment C of the Paris market operated by Euronext N.V. EnterNext, the NYSE Euronext subsidiary dedicated to promoting and growing the SME market, welcomed the new company, which will now benefit from its products and services.
Medtech specialises in designing, producing and marketing innovative robotic systems that assist neurosurgeons in cranial and spinal procedures. Using robots made entirely in France, the company has launched ROSA™, a ground-breaking solution designed to give surgeons new options for minimally invasive surgery. Unparalleled precision and ease of use are built into this new technology platform, whose leading-edge technology has been widely recognised and is protected by several international patent families.
Buoyed by growing demand from healthcare professionals, Medtech was elected Frost & Sullivan’s European Company of the Year for surgical robotics in 2013.
Medtech (ticker symbol: ROSA) was listed through the admission to trading of 1,647,920 shares making up the company’s equity and 740,741 new shares issued as part of a Global Offering , including full exercise of the extension clause and over-allocation option.
The admission and issue price of Medtech shares was set at €27 per share. Market capitalisation on the day of listing came to around €64.5 million. The total amount raised was around €20 million.
“We are delighted to welcome Medtech to our European market,” said EnterNext CEO Eric Forest. “And we are convinced that this listing will give the company fresh momentum as it expands in France and on international markets. Our entire EnterNext team will be working with Medtech to help it achieve its ambitious goals,” he added.
Bertin Nahum, Chairman & CEO and founder of Medtech, said: “I would like to thank all of the institutional and individual shareholders that have joined us, as well as all of our staff and partners, for their contributions to the success of our IPO. We will be going all out to ensure that our market performance lives up to the confidence you have demonstrated today.”
